# Langetermijnfollow-up van complete versus laesie-only revascularisatie bij STEMI: CvLPRIT

*geplaatst 2019-12-24 · Hartfalen · Journal of the American College of Cardiology · doi 10.1016/j.jacc.2019.10.033 · https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/*

CvLPRIT langetermijnfollow-up van complete versus culprit-only revascularisatie bij STEMI met multivatenlijden.

## English: Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMI and Multivessel Disease: The CvLPRIT Trial.

Long-term CvLPRIT follow-up confirmed that complete revascularization in STEMI with multivessel disease provides durable benefit over culprit-only PCI, with sustained event reduction over extended follow-up.

## Abstract (original, from the publication)

BACKGROUND: Randomized trials have shown that complete revascularization in patients with ST-segment elevation myocardial infarction (MI) with multivessel disease results in lower major adverse cardiovascular events (MACE) (all-cause death, MI, ischemia-driven revascularization, heart failure). OBJECTIVES: The goal of this study was to determine whether the benefits of complete revascularization are sustained long-term and their impact on hard endpoints. METHODS: CvLPRIT (Complete versus Lesion-only Primary PCI Trial) was a randomized trial of complete inpatient revascularization versus infarct-related artery revascularization only at the index admission. Randomized patients have been followed longer-term. The components of the original primary endpoint were collected from physical and electronic patient records, and from local databases for all readmissions. RESULTS: The median follow-up (achieved in >90% patients) from randomization to first event or last follow-up was 5.6 years (0.0 to 7.3 years). The primary MACE endpoint rate at this time point was 24.0% in the complete revascularization group but 37.7% of the infarct-related artery-only group (hazard ratio: 0.57; 95% confidence interval: 0.37 to 0.87; p = 0.0079). The composite endpoint of all-cause death/MI was 10.0% in the complete revascularization group versus 18.5% in the infarct-related artery-only group (hazard ratio: 0.47; 95% confidence interval: 0.25 to 0.89; p = 0.0175). In a landmark analysis (from 12 months to final follow-up), there was no significant difference between MACE, death/MI, and individual components of the primary endpoint. CONCLUSIONS: Long-term follow-up of the CvLPRIT trial shows that the significantly lower rate of MACE in the complete revascularization group, previously seen at 12 months, is sustained to a median of 5.6 years. A significant difference in composite all-cause death/MI favoring the complete revascularization was also observed. (Complete versus Lesion-only Primary PCI Trial; ISRCTN70913605).

Auteurs: Anthony H Gershlick, Amerjeet S Banning, Emma Parker, Duolao Wang, Charley A Budgeon, Damian J Kelly, Peter O Kane, Miles Dalby, Simon L Hetherington, Gerry P McCann, John P Greenwood, Nick Curzen

---
Bron: Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2019.10.033. Bijgewerkt 2026-07-03T13:27:31Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.